Overexpression of the melanoma dierentiation associated gene-7 (mda-7) in vitro results in suppression of lung cancer cell proliferation. However, the ability of MDA-7 to suppress lung cancer in vivo has not been previously demonstrated. In this study, we investigated the possibility of inducing overexpression of the mda-7 gene in human non-small cell lung carcinoma cells in vivo and its eects on tumor growth. Adenovirus-mediated overexpression of MDA-7 in p53-wild-type A549 and p53-null H1299 subcutaneous tumors resulted in signi®cant tumor growth inhibition through induction of apoptosis. In addition, decreased CD31/PECAM expression and upregulation of APO2/TRAIL were observed in tumors expressing MDA-7. In vivo studies correlated well with in vitro inhibition of lung tumor cell proliferation and endothelial cell dierentiation mediated by Ad-mda7. These data demonstrate that Ad-mda7 functions as a multi-modality anti-cancer agent, possessing both, pro-apoptotic and anti-angiogenic properties. We demonstrate for the ®rst time the potential therapeutic eects of Ad-mda7 in human lung cancer.
Introduction
Expression of the melanoma dierentiation associated gene-7 (mda-7) in actively proliferating normal melanocytes but not in melanoma cells has suggested that mda-7 may be a novel tumor suppressor gene (Jiang et al., 1995; Madireddi et al., 2000) . Jiang et al. (1996) demonstrated that mda-7 is a potent growth suppressor gene and selectively inhibits MDA-7-overexpressing cancer cells but not normal human cells. Additional evidence for the antitumor activity of mda-7 was demonstrated on MCF-7 tumor xenografts using adenoviral mda-7 (Ad-mda7) (Su et al., 1998) . Recently, we demonstrated that Ad-mda7 transduction into non-small cell lung cancer (NSCLC) cells and normal lung ®broblast cells induced growth suppression and apoptosis only in cancer cells but not in ®broblast cells (Saeki et al., 2000) . Apoptosis was induced through activation of caspases-9 and -3, which was independent of p53 and bax status (Saeki et al., 2000) . In a follow-up study, we demonstrated the antitumor eects of Ad-mda7 on a panel of more than 20-tumor cell lines derived from colon, breast, and lung . Endogenous MDA-7 protein expression was not detectable in the 20-tumor cell lines evaluated. However, MDA-7 protein expression was detectable in normal melanocyte and skin ®broblasts in culture (Ekmekcioglu et al., 2001) . Interestingly, expression of MDA-7 protein appears to be lost during melanoma disease progression (Ekmekcioglu et al., 2001) . These studies de®ne mda-7 as a novel tumor suppressor gene having a broad spectrum antitumor activity in vitro. Since ectopic MDA-7 expression appears to inhibit a diverse number of cancers, we evaluated the anti-tumor eects of Ad-mda7 expression against lung cancer cells in vivo and analysed the underlying mechanism involved in this tumor killing.
Results
In vitro expression of MDA-7 induces rapid apoptosis which leads to inhibition of tumor cell proliferation MDA-7 overexpression in tumor cells resulted in signi®cant growth inhibition of H1299 cells (27%) and inhibition of A549 cells (40%) at 72 h after infection ( Figure 1a ). In contrast, NHBE cells showed no signi®cant growth inhibition. Furthermore, tumor cells but not normal cells transduced with Ad-mda7 underwent apoptotic cell death (Figure 1b) . Few of the tumor cells transduced with Ad-luc demonstrated apoptotic changes. Semi-quantitative analysis demonstrated 13% of H1299 and 19% of A549 cells expressing MDA-7 undergoing apoptotic cell death (Figure 1c ).
MDA-7 overexpression inhibited endothelial cell differentiation in vitro
Prior to start of the experiment HUVEC's were analysed for endogenous MDA-7 expression by Western blot analysis. Endogenous MDA-7 expression was not detectable. However, treatment with Ad-mda7 resulted in sustained MDA-7 expression from days 1 through 4 (Figure 2a ). Based on this observation we next evaluated the ability of Ad-mda7 to inhibit endothelial cell dierentiation in HUVEC cells and compared to the cell cycle regulator p16 (Ad-p16). Overexpression of MDA-7 and p16 resulted in inhibition of endothelial tube formation (Figure 2b ). However, tube formation was only partially inhibited in the Ad-p16 treated cells with fully formed tubes and hemi-tubes being evident in these cultures in addition to elongated tube-like structures. In contrast Ad-mda7 treated cells showed no evidence of tube formation and appeared rounded up similar to the cells treated with suramin, a known inhibitor of tube formation (Figure 2b ). Thus the extent of inhibition was greater in Ad-mda7 infected cells than in Ad-p16 infected cells. Cells infected with control vector (Ad-luc) demonstrated no inhibition of tube formation. Inhibition of tube formation by endothelial cells was due to MDA-7 overexpression and not due to cytotoxicity was determined by alamar blue assay for cell viability (Figure 2c ). Transduction with varying MOI's of Ad-mda7 demonstrated no signi®cant toxicity compared with cells transduced with Ad-luc. Thus the inhibition of tube formation by endothelial cells suggests that Ad-mda7 may possess antiangiogenic activity in vivo (see below).
To further determine the eects of Ad-mda7 on HUVEC's, cell cycle analysis was performed. A signi®cant reduction in the S phase and a slight increase in G 1 phase cells was observed in both Adluc and Ad-mda7 treated cells when compared to control cells treated with PBS (Figure 2d ). However, no signi®cant dierences was observed in the G 2 /M phase between Ad-mda7, Ad-luc, and PBS treated cells indicating that Ad-mda7 does not induce speci®c cell cycle block in HUVECs. In addition, no signi®cant dierence was observed in the SubG 0 /G 1 fraction, indicative of apoptotic cells, between control cells (1.0%), Ad-luc (1.1%) and Ad-mda7 (1.12%) treated cells (data not shown).
MDA-7 overexpression induces TRAIL and DR4 expression in vitro
Tumor and normal cells treated with Ad-mda7 were analysed for TRAIL and DR4 expression and compared to untreated control cells. Upregulation of TRAIL and DR4 was observed in both, H1299 and A549 tumor cells after Ad-mda7 treatment (Figure 3 ). TRAIL expression was observed to be increased on day 1 in H1299 cells and on day 3 in A549 cells while DR4 expression was observed to be increased from day 2 in both tumor cells. In contrast, no change in neither TRAIL, nor DR4 expression was observed in NHBE cells at all time points tested.
In vivo evaluation of local tumor growth suppression by Ad-mda7
We assessed the therapeutic eects of intratumoral injection of Ad-mda7 on A549 and H1299 subcutaneous tumors in nude mice. Signi®cant inhibition of the growth of both H1299 tumors (P=0.01) and A549 tumors (P=0.001) was observed in mice treated with Ad-mda7 but not in the control groups that were either not treated or treated with Ad-luc ( Figure 4 ).
Further evidence that this therapeutic eect was due to MDA-7 overexpression was demonstrated by immuno- Figure 5a ). In addition, expression of MDA-7 was also observed in few endothelial cells MDA-7 expression was observed in 15% of the tumor cells (P=0.001) from animals that were treated with Ad-mda7 (Figure 5b ). MDA-7 expression was not detected in tumors that were either not treated or treated with Ad-luc.
To understand the mechanism of tumor inhibition mediated by MDA-7, subcutaneous tumors were analysed for apoptotic tumor cell death by TUNEL staining. Tumors from mice treated with Ad-mda7 demonstrated extensive apoptosis (17%) (Figure 5c ,d) whereas tumors from animals treated with Ad-luc showed minimal apoptotic cell death (3%). ) and normal bronchial epithelial cells (NHBE) were transduced with Ad-mda7 (5000 v.p./cell) and analysed for MDA-7, TRAIL, and its receptor DR4 expression by Western blot analysis on days 1 ± 5. Uninfected cells served as controls. Upregulation of TRAIL and DR4 was observed in tumor cells but not in normal cells at all time points tested. However, TRAIL expression was observed to be upregulated on day 1 in H1299 cells and on day 3 in A549 cells while DR4 expression was observed to be upregulated on day 2 in both tumor cell lines Figure 4 Therapeutic eect of Ad-mda7 treatment on subcutaneous human lung cancer xenografts. Subcutaneous H1299 (a) and A549 (b) tumor-bearing mice were divided into three groups (eight animals per group) and treated on alternate days for a total of three doses (5610 9 v.p./dose), as follows: no treatment (solid circles), Ad-luc (open squares) or Ad-mda7 (solid squares). Tumors were measured using calipers, and the statistical signi®cance of tumor volume changes were calculated using the Student's t-test. Tumors treated with Ad-mda7 showed signi®cant growth inhibition (P=0.01) compared to tumors treated with Ad-luc or untreated. Each time point represents the mean tumor volume for each group. Bars represent standard errors
Overexpression of MDA-7 induced downregulation of CD31 and upregulation of TRAIL in experimental tumors
To further de®ne the tumor-suppressive eects of MDA-7, subcutaneous tumors were analysed for expression of CD31, a marker routinely used to identify neoangiogenesis in tumors. Tumors treated with Ad-mda7 had signi®cantly less number of CD31 positive staining vessels (9; P=0.001) than in tumors treated with Ad-luc (28) or no treatment (39) (Figure  6a,c) . Similarly, analysis for expression of TRAIL, a promoter of apoptosis, demonstrated higher levels of TRAIL expression in tumors treated with Ad-mda7 (20%; P=0.001) than in tumors that were treated with Ad-luc (4%) or untreated (1%) (Figure 6b,d ).
Discussion
Overexpression of MDA-7 inhibits proliferation and induces apoptosis of cancer cells (Jiang et al., 1996; Su et al., 1998; Mhashilkar et al., 2001) . The anticancer activity of mda-7 was recently demonstrated both in vitro and ex vivo using breast cancer cells (Su et al., 1998) . However, the underlying mechanism of tumor killing by mda-7 was not established in that study. We recently demonstrated in vitro, in lung cancer cell lines, that Ad-mda7-mediated tumor cell killing is independent of p53 and bax expression and occurs through activation of the caspase cascade (Saeki et al., 2000) . In the present study, we extend our ®ndings on the antitumor activities of Ad-mda7 to lung tumor xenografts in vivo.
Xenograft tumors that expressed wild-type p53 (A549) or were null for p53 (H1299) when treated with Ad-mda7 demonstrated signi®cant growth inhibition. The ability of MDA-7 to inhibit both A549 and H1299 tumors and induce apoptosis supports the in vitro ®ndings presented here as well as our previous in vitro results (Saeki et al., 2000; Mhashilkar et al., 2001) . Immunohistochemical analysis of tumor tissues revealed MDA-7 expression primarily in the tumor cells. However, MDA-7 expression was also observed in few endothelial cells. Expression was observed in the cytoplasm of cells similar to that observed in vitro (Saeki et al., 2000; Mhashilkar et al., 2001) . In addition, extracellular staining was also observed in some areas of the tumors indicating MDA-7 may be secreted. Presence of soluble MDA-7 has been demonstrated in vitro . Although soluble MDA-7 has been previously demonstrated its role in mediating tumor cell cytotoxicity is unknown. Furthermore, immunohistochemical analysis revealed that induction of widespread apoptosis and tumor inhibition occurred through caspase-3 activation (data not shown).
To identify any additional mechanisms for the observed antitumor activity of MDA-7, we evaluated the antiangiogenic properties of Ad-mda7 both in vitro and in vivo. In vitro experiments showed HUVEC's to be negative for endogenous MDA-7 expression. However, following MDA-7 overexpression endothelial cell dierentiation (tube formation) was inhibited. Dierentiation of endothelial cells into tube-like structures is an in-vitro correlate for micro-capillary formation in neo-angiogenesis. To further determine whether the observed inhibitory eect was speci®c or a general eect that could be mediated by a variety of cell cycle regulators, we compared MDA-7 with p16. Inhibition of endothelial cell dierentiation though observed with both Ad-p16 and Ad-mda7 the extent of inhibition was much less in Ad-p16 treated cells as evidenced by the presence of fully formed tubes and hemi-tubes. In contrast, Ad-mda7 treated cells demonstrated complete inhibition of tube formation, an eect similar to that observed with suramin. Thus, it is reasonable to say that MDA-7 exerts a stronger inhibitory eect on HUVEC's than p16. Similarly, evaluation for CD31 expression, a marker highly expressed by neoangiogenic endothelial cells, in tumors treated with Ad-mda7 demonstrated few blood vessels as evidenced by the relatively low level of CD31-positive staining (Vecchi et al., 1994; Orre and Rogers, 1999) . The ability of Ad-mda7 to inhibit angiogenesis is comparable to that observed in tumors treated with Ad-p53 in a previous study (Nishizaki et al., 1999) . Additional evidence that MDA-7 has antiangiogenic properties stems from our in vitro ribonuclease protection assays. Overexpression of MDA-7 in lung tumor cells resulted in downregulation of VEGF and transforming growth factor-beta (TGF-b) mRNA (data not shown), all known modulators of angiogenesis (Rowe et al., 2000; Jain et al., 1996; Roberts and Sporn, 1989) . It is also possible that mda-7, which shares low level of homology with interleukin 10 (IL-10) inhibits angiogenesis similar to that observed with IL-10 ( Kundu et al., 1998) . Since the exact function of mda-7 and its interactions with other genes are unknown, we evaluated the eects of Ad-mda7 on the expression of other genes by microarray analysis. Microarray experiments demonstrated higher levels of TRAIL and its receptor DR4/DR5 in Ad-mda7-treated tumor cells (data not shown) than in cells treated with Ad-luc or PBS. This observation correlated with our in vitro results where increased TRAIL and its receptor (DR4) expression was observed in tumor cells but not in normal cells when treated with Ad-mda7. TRAIL, a member of the tumor necrosis factor (TNF) family, has been previously demonstrated to induce apoptosis in cancer cells both in vitro and in vivo (Grith et al., 2000; Walczak et al., 1999) . Kagawa et al. (2001) recently demonstrated that overexpression of TRAIL results in antitumor activity against lung and prostate cancer cells. Furthermore, in the same study, TRAIL mediated bystander eects were demonstrated. Based on these ®ndings, we examined tumor tissues for TRAIL expression and observed upregulation of TRAIL in Ad-mda7 treated tumors but not in control tumors. The discrepancy observed in the regulation of TRAIL expression in vitro and in vivo of H1299 cells may be due to dierences in the kinetics of vector uptake and gene expression. The mechanism by which TRAIL expression is upregulated in cancer cells overexpressing MDA-7 is not clear. These ®ndings suggest that MDA-7 may induce expression of proapoptotic molecules such as TRAIL and enhance apoptotic tumor cell killing.
Alternatively, p53 expression can upregulate TRAIL and its receptors (Sheikh and Fornace, 2000) . In our previous study evaluating pro-apoptotic eects of Admda7 in lung cancer cells in vitro, we demonstrated that Ad-mda7 selectively increases steady state levels of p53 protein in p53 wild-type tumor cells, but not in normal cells resulting in apoptotic cell death (Saeki et al., 2000) . A similar phenomenon can occur in Admda7 treated A549 xenograft tumors that are wildtype for p53 resulting in upregulation of TRAIL. However, the ability of Ad-mda7 to upregulate TRAIL in H1299 (p53-null) tumors suggests that p53-independent mechanisms must exist. Whatever the underlying mechanism may be for TRAIL induction, we believe that the primary tumor killing is due to MDA-7 overexpression and that TRAIL might augment the bystander tumor killing eect. This is based on the in vitro observation that in Ad-mda7 treated A549 tumor cells MDA-7 expression is detectable as early as 24 h with initiation of apoptosis at 48 h. In contrast, TRAIL is signi®cantly upregulated only at 72 h.
Although the molecular mechanism responsible for the antitumor eects of Ad-mda7 are still under investigation, this study demonstrated for the ®rst time the antitumor and antiangiogenic activities of MDA-7 in lung tumor xenografts. The combination of tumor selective pro-apoptotic activity with anti-angiogenic properties suggest that Ad-mda7 may be a powerful therapeutic agent for cancer.
Materials and methods

Cell culture
Human NSCLC cell lines A549 (adenocarcinoma) and H1299 (large cell lung carcinoma) were obtained and maintained as described previously (Saeki et al., 2000) . Normal human bronchial epithelial cells (NHBE), and human umbilical vein endothelial cells (HUVEC) were purchased from Clonetics (Walkersville, MD, USA) and maintained as recommended by Clonetics.
Construction of the recombinant adenoviral vector
Construction, and puri®cation of adenoviral vector (Ad5) carrying the mda-7 (Ad-mda7) gene has been described previously (Saeki et al., 2000) . 
Cell proliferation assay
Endothelial cell differentiation (tube formation) assay
Human umbilical vein endothelial cells (HUVECs) were seeded on 1% gelatin-coated plates and incubated at 378C for 24 h. After incubation, cells were treated for 1 h with Adluc, Ad-mda7, or Ad-p16 at 10 000 v.p./cell in serum-free medium. Cells exposed to medium alone served as negative controls while cells exposed to Suramin (50 mM) served as positive controls. After a 48 h incubation period (378C in serum-containing medium), infected cells were harvested, counted, and added to Matrigel-coated 24-well plates in triplicate (1.2610 5 cells per well). Twenty-four hours later, cells were ®xed with 10% buered formalin and examined for dierentiation (tube formation) using an Olympus IX-70 inverted bright-®eld microscope at 46 and 106 magni®ca-tion.
Alamar blue assay
To determine the growth inhibitory eects of Ad-mda7 on HUVEC's, cells were plated at 10 4 cells per well in a 96-well plate and infected with Ad-mda7 or Ad-luc in triplicates with 0, 100, 250, 500, 1000, 2500, 5000 and 10 000 viral particles per cell. Three days post-infection, 20 ml of alamar blue dye was added to each well and the plate was incubated at 378C for 6 ± 8 h. The plates were then processed for optical density absorbance analysis using the Dynatech MRX plate reader at dual wavelengths of 575 and 600 nm. Revelation 3.2 software program was used to analyse the data.
Cell cycle analysis
HUVEC cells (5610 5 ) were treated with Ad-luc or Ad-mda7 (10 000 v.p./cell) in 6-well plates. Cells were harvested 48 h later and subjected to cell cycle analysis as described previously (Saeki et al., 2000) . Uninfected cells served as negative controls.
Western blot analysis
Cells (1610 5 ) treated with Ad-mda7 (5000 v.p./cell) were harvested by trypsinization on days 1 ± 5 and analysed for MDA-7, DR4 and TRAIL expression by Western blot analysis as described previously (Saeki et al., 2000) . Cells receiving no treatment served as controls. Antibodies against DR4 (1 : 1000), and TRAIL (1 : 1000) were purchased from MDA-7 expression inhibits lung cancer growth T Saeki et al Pharmingen (San Diego, CA, USA) and for MDA-7 (1 : 2500) from Introgen Therapeutics, Inc. (Houston, TX, USA).
Evaluation of tumor growth in vivo
Subcutaneous tumor xenografts (A549, H1299) were established in the right dorsal¯ank of nu/nu mice as described previously . When the tumor has reached a size of 50 ± 100 mm 3 , animals were randomized into three groups (n=8 animals per group) and treatment was initiated as follows. Group 1 received no treatment; Group 2 received Ad-luc (5610 9 v.p./dose); and Group 3 received Ad-mda7 (5610 9 v.p./dose); all treatments were given every other day for a total of three doses. Intratumoral injections were performed under methoxy¯ur-ane anesthesia (Schering Plough, Kenilworth, NJ, USA) as per institutional guidelines. Tumor measurements were recorded every other day without knowledge of the treatment groups as described previously (Georges et al., 1993) . Experiments were terminated when tumors showed signs of necrosis. Antitumor ecacy data are presented as average tumor volumes for all animals in each group to account for both size and number of tumors.
Immunohistochemical analysis
Xenograft tumors established in nude mice were harvested and ®xed in 10% buered formalin, embedded in paran, and cut in 4-mm sections. Sections were stained for MDA-7 expression as described previously (Saeki et al., 2000) using rabbit polyclonal anti-MDA7 antibody (Introgen Therapeutics, Houston, TX, USA) for 60 min. Expression of the MDA-7 protein in tissues was detected with DAB by enhancement with avidin-biotin reaction ABC kit (Vector Laboratories, Burlingame, CA, USA). The slides were then counterstained with hematoxylin and mounted with Aquamount (Lerner Laboratories, Pittsburgh, PA, USA). Similar staining procedures were followed using anti-mouse CD31 (1 : 500, Pharmingen, San Diego, CA, USA) and antihuman TRAIL (1 : 1000, Pharmingen, San Diego, CA, USA) antibodies. Negative controls included tissue sections stained without primary antibody. Tissue sections were analysed, quantitated and results interpreted in a blind fashion.
TUNEL staining
Tumor tissues were stained to detect apoptotic cell death using the terminal deoxynucleotide transferase (Tdt) kit (Boehringer Mannheim, Indianapolis, IN, USA) as described previously .
Statistical analysis
Student's t-test was used to calculate the statistical signi®cance of the experimental results.
